BAY 11-7082 (Synonyms: BAY 11-7821)

Name: BAY 11-7082
Brand: MedChemExpress
SKU: HY-13453
Rating: 5.0 (328 reviews)

Cat. No.: HY-13453 Purity: 99.93%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

BAY 11-7082 is an IκBα phosphorylation and NF-κB inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 (IC₅₀=0.19, 0.96 μM, respectively). BAY 11-7082 inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells.

For research use only. We do not sell to patients.

BAY 11-7082 Chemical Structure

CAS No. : 19542-67-7

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 61	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 61	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 55	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 66	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 231	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 374	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 328 publication(s) in Google Scholar

310 Publications Citing Use of MCE BAY 11-7082

RT-PCR

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2019 Mar;120(3):3898-3910. [Abstract]; Cells pretreated with SP600125 show a decreased proapoptotic Bax expression and increase antiapoptotic Bcl-2 formation when JNK pathway is blocked. Inhibition of p38 by SB202190 significantly enhanced Bcl-2 expression. Pretreatment with BAY 11-7082 to inhibit NF‐κB markedly enhance Baxm and decrease Bcl-2 expression compared with the ACR-treated group.

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: BMC Cancer. 2019 Jan 8;19(1):30. [Abstract]; The representative images and analysis of western blot for IκBα、p-IκBα and nuclear p65 in CRC cells and expression levels of E-cadherin, N-cadherin and fibronectin in SW620 and HCT116 cells are measured by western blot treated with BAY 11-7082 (inhibitor of NF-κB pathway).

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: Evid-Based Compl ALlt. 2019 Jan 13;2019:9406342. [Abstract]; The expressions of p-p65, COX-2 and AQP3 are detected by western blotting with or without the treatment of BAY and RFP.

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: Evid-Based Compl ALlt. 2019 Jan 13;2019:9406342. [Abstract]; Protein expressions of AQP3, COX-2 and p-P65 are analyzed by western blot analysis with or without the treatment of BAY and RFP.

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Aug 1;428:77-89. [Abstract]; Western blots show that the NF-κB inhibitors BAY11-7082, Parthenolide, and JSH-23 cause dramatic time- and dose-dependent reductions in MGMT protein expression in LN18 and T98G glioma cells.

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291. [Abstract]; Real-time PCR analysis shows that meningitic E. coli strains PCN033- and RS218-induced proinflammatory cytokines production is significantly decreased via NF-κB signaling inhibition with 10 μM of BAY11-7082.

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291. [Abstract]; Real-time PCR analysis shows that meningitic E. coli strains PCN033- and RS218-induced proinflammatory cytokines production is significantly decreased via NF-κB signaling inhibition with 10 μM of BAY11-7082.

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Aug 29;9(9):880. [Abstract]; NF-κB inhibitor Bay 11-7082 treatment inhibits the activation of SOX4 and EMT process induced by CXCL1.

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2018 Mar;75(6):1117-1132. [Abstract]; Sertoli cells (SC) are pretreated with BAY11-7082 at 2 μM for 1 h, followed by the addition of MC-LR into the culture medium. Expression of p-p65 and MMP-8 is measured by western blotting.

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2018 Jul;75(14):2627-2641. [Abstract]; RAW264.7 macrophages are pre-treated with the inhibitor of ERK, JNK, P38, P65, and AKT signal pathway.Western blot analyzes the non- and phosphorylation of ERK, JNK, P38, P65, and AKT.

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: Front Immunol. 2018 Sep 19;9:2121. [Abstract]; RPMI 2650 cells is incubated with or without IL-17A (100 ng/mL)+BAY 11-7082 (5 μM) for 24 h. WB is performed to measure the expression of MMP-9 protein levels.

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: Lab Invest. 2018 Apr;98(4):462-476. [Abstract]; Caco-2BBe cells are pretreated with BAY-11-7082 for 30 min and then treated with TNF-α (100 ng/mL) for 6 h. BAY-11-7082 treatment prevented the TNF-α-induced decrease in downregulated in adenoma (DRA).

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: Cancer Biol Ther. 2018 Mar 4;19(3):222-229. [Abstract]; Western blot analysis of PIK3R3, TP, p-P65, P65 expression after transfected with PIK3R3 at the presence of BAY11-7082.

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: Environ Pollut. 2017 Oct;229:964-975. [Abstract]; NF-κB-dependent immune responses in testicular cells. Sertoli cells (SC), Leydig cells (LC), and germ cells (GC) are pretreated with BAY11-7082 (BAY) at 2 μM for 1 h, followed by the addition of MC-LR into the culture medium to a final concentration of 1 μM and incubation for 6 h. Expression of phosphorylated NF-κB p65 (p-p65) and total p65 is measured by western blotting. The ratio of p-65/p65 is determined by densitometry and is expressed as means±SEM (n=5).

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: Eur J Med Chem. 2017 Oct 20;139:337-348. [Abstract]; The cells are treated with different concentrations of compound 6k, and then in the presence or absence of LPS (1 μg/mL) for 24 h. Bay 11-7082 is the NF-κB inhibitors (20 μM). The results are showed as means±SD (n=3) of at least three independent experiments.

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2017 Sep;50:30-37. [Abstract]; BV-2 cells are pretreated with or without Bay11-7082 (10 μM) for 30 min, and then incubated with 20 μM Aβ_1–42 for 24 h. The protein expression of TNF-α, IL-1β, and IL-6 are detected by western blot.

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2017 Mar 22;323:44-52. [Abstract]; The HUVECs are subjected to NF-κB inhibitor BAY 11-7082 (10 μM) for 1 h prior to MGO (1.0 mM) treatment for 24 h, then Bcl-2/ Bax ratio are determined by western blot.

: BAY 11-7082 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2016 Oct;39:149-57. [Abstract]; AOPPs-induced increase in catabolic factors is regulated by NF-κB activation. Chondrocytes are pretreated with or without NF-κB specific inhibitor Bay11-7082 (0.5 μM), followed by AOPPs treatment. NF-κ B p65 phosphorylation, IκB-α degradation and catabolic factors are detected by Western blot analysis. GAG production is determined by DMB method. Addition of Bay11-7082 blocks AOPPs-induced phosphorylation of NF-κB p65 and prevents degradation of IκB-α.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All IKK Isoform Specific Products:

View All Isoforms

IKK-α IKK-β IKK IKKε TBK1

View All Deubiquitinase Isoform Specific Products:

View All Isoforms

USP1 USP2 USP7 USP8 USP30 UCHL1

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[2]

NF-κB

USP7

0.19 μM (IC₅₀)

USP21

0.96 μM (IC₅₀)

Autophagy

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	11 μM Compound: BAY-11-7082	Inhibition of TNFalpha-induced NFkappaB activation in human HEK293 cells after 6 hrs by luciferase assay Inhibition of TNFalpha-induced NFkappaB activation in human HEK293 cells after 6 hrs by luciferase assay	[PMID: 32163285]
HEK293	IC₅₀	2 μM Compound: BAY-11	Inhibition of TNFalpha-induced NF-kappaB activity (unknown origin) transfected in HEK293 cells after 6 hrs by luciferase reporter gene assay Inhibition of TNFalpha-induced NF-kappaB activity (unknown origin) transfected in HEK293 cells after 6 hrs by luciferase reporter gene assay	[PMID: 26343828]
HEK293	IC₅₀	2 μM Compound: BAY-11	Inhibition of TNF-alpha-induced NF-kappaB activity in HEK293 cells after 6 hrs by luciferase reporter gene assay Inhibition of TNF-alpha-induced NF-kappaB activity in HEK293 cells after 6 hrs by luciferase reporter gene assay	[PMID: 24992702]
HEK293	IC₅₀	2 μM Compound: BAY-11	Inhibition of TNF-alpha-induced NF-kappaB activity in HEK293 cells after 6 hrs by luciferase reporter gene assay Inhibition of TNF-alpha-induced NF-kappaB activity in HEK293 cells after 6 hrs by luciferase reporter gene assay	[PMID: 24533857]
HEK293	IC₅₀	2 μM Compound: BAY-11	Inhibition of TNFalpha-induced NF-kappaB activity expressed in human HEK 293 cells after 6 hrs by luciferase reporter gene assay Inhibition of TNFalpha-induced NF-kappaB activity expressed in human HEK 293 cells after 6 hrs by luciferase reporter gene assay	[PMID: 22850207]
HEK293	IC₅₀	2.01 μM Compound: BAY-11, BAY-117028	Inhibition of TNFalpha-induced human NFkappaB activity in HEK293 cells incubated for 6 hrs followed by compound wash out measured after 5 mins by by luciferase assay Inhibition of TNFalpha-induced human NFkappaB activity in HEK293 cells incubated for 6 hrs followed by compound wash out measured after 5 mins by by luciferase assay	[PMID: 22712432]
HEK293	IC₅₀	5 μM Compound: BAY-11	Inhibition of TNFalpha-induced NFkappaB (unknown origin) activation expressed in HEK293 cells after 6 hrs by luciferase reporter gene assay Inhibition of TNFalpha-induced NFkappaB (unknown origin) activation expressed in HEK293 cells after 6 hrs by luciferase reporter gene assay	[PMID: 23316950]
RAW264.7	IC₅₀	1.72 μM Compound: BAY11-7082	Inhibition of LPS-induced NF-kappaB activation in mouse RAW264.7 cells treated 30 mins before LPS challenge measured after 6 hrs by luciferase reporter gene assay Inhibition of LPS-induced NF-kappaB activation in mouse RAW264.7 cells treated 30 mins before LPS challenge measured after 6 hrs by luciferase reporter gene assay	[PMID: 24315191]
RAW264.7	IC₅₀	5180 nM Compound: BAY11-7082	Inhibition of LPS stimulated TNF-alpha production in mouse RAW264.7 macrophages preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by EIA Inhibition of LPS stimulated TNF-alpha production in mouse RAW264.7 macrophages preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by EIA	[PMID: 33601311]
SH-SY5Y	IC₅₀	0.85 μM Compound: Bay 11-7082	Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay	[PMID: 36208544]
SK-N-AS	IC₅₀	1.23 μM Compound: Bay 11-7082	Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay	[PMID: 36208544]

In Vitro

BAY 11-7082 (BAY 11-7821), an inhibitor of NF-κB, induces apoptosis of HTLV-I-infected T-cell lines but only negligible apoptosis of HTLV-I-negative T cells. Bay 11-7082 rapidly and efficiently reduces the DNA binding of NF-κB in HTLV-I-infected T-cell lines and down-regulated the expression of the antiapoptotic gene, Bcl-xL, regulated by NF-κB. Bay 11-7082 selectively inhibits Tax-induced NF-κB activity in a human T-cell line^[1].
BAY 11-7082 inhibits NFκB signalling and is recently shown to inhibit the majority of E2 and E3 ligases tested by reacting covalently with the catalytic cysteine residues. Moreover, BAY 11-7082 also inhibits several tyrosine phosphatases by reacting with catalytic Cys residue of these enzymes. NSC 697923 is originally shown to inhibit the E2 ligase Ubc13-Uev1A^[2].
BAY 11-7082 inhibits the phosphorylation of IκBα and activation of NF-κB, induces the death of HBL-1 cells. BAY 11-7082 completely suppresses the LPS-stimulated and IL-1-stimulated phosphorylation of the activation loop of IKKβ^[3].
BAY 11-7082 acts by inhibiting TNF-α-induced phosphorylation of IκB-α, resulting in decreased NF-κB and decreases expression of adhesion molecules^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BAY 11-7082 (2.5 mg/kg and 5 mg/kg; intratumoral injection; twice-weekly for 21 days ) significantly suppresses tumor growth in a dose-dependent manner^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Four-week-old male BALB/c nude mice with human gastric carcinoma cell lines HGC-27^[6]
Dosage:	Low-dose (2.5 mg/kg body weight), high-dose (5 mg/kg body weight)
Administration:	Intratumoral injection; twice-weekly for 21 days
Result:	Suppressed tumor growth in a dose-dependent manner.

Molecular Weight

207.25

Formula

C₁₀H₉NO₂S

CAS No.

19542-67-7

Appearance

Solid

Color

White to off-white

SMILES

N#C/C=C/S(=O)(C1=CC=C(C)C=C1)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (482.51 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.8251 mL	24.1255 mL	48.2509 mL
5 mM	0.9650 mL	4.8251 mL	9.6502 mL
10 mM	0.4825 mL	2.4125 mL	4.8251 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (12.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (12.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.98%

Select Batch:

Data Sheet (280 KB) SDS (251 KB)

COA (248 KB) RP-HPLC (254 KB)

Handling Instructions (2659 KB)

References

[1]. Mori N, et al. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines andprimary adult T-cell leukemia cells. Blood. 2002 Sep 1;100(5):1828-1834. [Content Brief]

[2]. Ritorto MS, et al. Screening of DUB activity and specificity by MALDI-TOF mass spectrometry. Nat Commun. 2014 Aug 27;5:4763. [Content Brief]

[3]. Strickson S, et al. The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. Biochem J. 2013 May 1;451(3):427-437. [Content Brief]

[4]. Pierce JW, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem. 1997 Aug 22;272(34):21096-103. [Content Brief]

[5]. Jun Jacob Hu, et al. Identification of pyroptosis inhibitors that target a reactive cysteine in gasdermin D. The Preprint Server For Biology, 2018,Jul. 10.

[6]. Chen L , et al. BAY 11-7082, a nuclear factor-κB inhibitor, induces apoptosis and S phase arrest in gastriccancer cells. J Gastroenterol. 2014 May;49(5):864-74. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.8251 mL	24.1255 mL	48.2509 mL	120.6273 mL
	5 mM	0.9650 mL	4.8251 mL	9.6502 mL	24.1255 mL
	10 mM	0.4825 mL	2.4125 mL	4.8251 mL	12.0627 mL
	15 mM	0.3217 mL	1.6084 mL	3.2167 mL	8.0418 mL
	20 mM	0.2413 mL	1.2063 mL	2.4125 mL	6.0314 mL
	25 mM	0.1930 mL	0.9650 mL	1.9300 mL	4.8251 mL
	30 mM	0.1608 mL	0.8042 mL	1.6084 mL	4.0209 mL
	40 mM	0.1206 mL	0.6031 mL	1.2063 mL	3.0157 mL
	50 mM	0.0965 mL	0.4825 mL	0.9650 mL	2.4125 mL
	60 mM	0.0804 mL	0.4021 mL	0.8042 mL	2.0105 mL
	80 mM	0.0603 mL	0.3016 mL	0.6031 mL	1.5078 mL
	100 mM	0.0483 mL	0.2413 mL	0.4825 mL	1.2063 mL

BAY 11-7082 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

BAY 11-7082 (Synonyms: BAY 11-7821)

Customer Review

310 Publications Citing Use of MCE BAY 11-7082

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All IKK Isoform Specific Products:

View All Deubiquitinase Isoform Specific Products:

View All NF-κB Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

BAY 11-7082 Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

BAY 11-7082 (Synonyms: BAY 11-7821)

Customer Review

BAY 11-7082 Related Antibodies

310 Publications Citing Use of MCE BAY 11-7082

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All IKK Isoform Specific Products:

View All Deubiquitinase Isoform Specific Products:

View All NF-κB Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

BAY 11-7082 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

BAY 11-7082 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report